Some Americans still resist genetic testing for fear they will be discriminated against by insurance companies.  Why?

in 2008, Congress passed GINA, the Genetic Information Nondiscrimination Act, to protect us from insurance companies choosing to include us or not for policies based on the genes we came with.    Then in 2010, Congress passed the ACA, or Affordable Care Act, and with it protection against preexisting conditions.  This includes genetic predispositions. 

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Anya Prince on Our Current Vulnerability to Genetic Discrimination

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine. 

www.mendelspod.com

Tech News

Technology

Natural Sciences

Science & Medicine

Social Sciences

Medicine

News

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

Today, we continue our look into the gap in the adoption of precision medicine. Why are those who need it not getting genetic testing? Patrick Short is the Host of The Genetics Podcast and CEO and Co-founder of Sano Genetics.

The Pre-Symptomatic Space with Patrick Short, Sano Genetics

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

Through its Center for Personalized Medicine, the University of Colorado Health offers its 2.2 million patients some of the country's most advanced precision medicine initiatives.

Systemwide Implementation of Precision Medicine at UCHealth with David Kao

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

A  new spatial biology company is promising to shake up the field. Last month, Curio Bioscience launched a new technology to early access customers that provides transcriptomic spatial data without the need to b…

Is this New Tech a Game Changer for Spatial Biology?

John Cumbers is back on the show to preview the annual SynBioBeta, the leading global conference for the synthetic biology crowd. This year’s show includes 18 tracks on AI, space, longevity, and DNA synthesis. Speakers will include Stephen Wolfram and Stephen Quake, who will discuss large language models and biology. While 2024 saw a total investment of over $6 billion (not as high as the pandemic year of 2021), John says the new technologies and startups keep coming. "We’re seeing just a ton of new entrepreneurs coming out of graduate and undergraduate programs and starting companies.” John is the founder and CEO of SynBioBeta which takes place May 6-9th in the San Jose Convention Center. 

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Synthetic Biology in 2024 with John Cumbers

Most of the news coming from Illumina has had to do with their leadership in the sequencing instrument space. What is lesser known is that they offer an end-to-end solution for the clinical lab, including variant calling and genome interpretation.In this podcast, we’re joined by Sam Strom, Principal Scientist at Illumina and a certified Clinical Lab Director.  Sam comes to Illumina from the clinical testing side; for example, he’s co-chair for the expert curation panel for Parkinson’s Disease and sits on a working group at ClinGen.In the interview, Sam addresses two of the big challenges in clinical sequencing, which are variant calling and variant interpretation. Sam says Illumina has created its own multi-sample genomic reference and is also making use of artificial intelligence to improve variant calling. He also shares how Illumina supports scaling variant interpretation for genomes and other assays with an AI and automation comprehensive solution, enabling high-quality genetic testing workflows to reach next level accessibility.“I think we’re going to see more “lights out” testing where there really isn’t an interpretation component to the test.   It’s a pure technical test.  It has certain limitations.  But it gets you 99.9% of the way there.  The technology is ready." 

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Anya Prince on Our Current Vulnerability to Genetic Discrimination

Download our free app to listen on your phone